{"schema":"sb.node.v1","id":"sb:e/462b84684a545ddec9d48a09","kind":"entity","label":{"text":"parp","locale":"en"},"identity":{"anchor":"label:en:parp","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-06T14:59:38.550729+00:00","snapshot":"deploy d24d0083c364efac0c7a986b84521060def7f044"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":20,"separatePublishers":11,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim"},"admission":{"state":"provisional","reason":"entity graph provenance 'observed'; the node carries no promotion receipt in v1","policy":"EQ-PROMOTION (receipt not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-01","to":"2026-10-05","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.15: about 85% of mentions carry no typed assertion"]}},"dimensions":{"domains":["precision_medicine","auto"],"activeDays":11,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":12,"byKind":{"observation":12},"items":[{"id":"sb:o/4361e1fb64ab5bdc04f4163c","kind":"observation","label":"bioRxiv Cancer Biology · 2026-09-23 · Longitudinal transcriptomic analysis reveals adaptive transcript usage remodeling associated with PARP inhibitor resistance","url":"https://www.biorxiv.org/content/10.64898/2026.09.22.753421v1?rss=1"},{"id":"sb:o/09b91f121800cf5d24c6d0b8","kind":"observation","label":"bioRxiv Cancer Biology · 2026-09-18 · TALAVE in Breast Cancer: BRCA1/2 Mutation-Dependent Immune Remodeling after PARP Inhibition with Limited Checkpoint Engagement","url":"https://www.biorxiv.org/content/10.64898/2026.09.17.752386v1?rss=1"},{"id":"sb:o/24e59257e90cecb474c8924a","kind":"observation","label":"Front Cell Dev Biol · 2026-09-01 · PARP inhibitors across different malignancies: clinical applications, resistance mechanisms, and strategies to enhance efficacy through combination therapies.","url":"https://doi.org/10.3389/fcell.2026.1891797"},{"id":"sb:o/e9505617dd7940369c6a8969","kind":"observation","label":"Fierce Biotech · 2026-10-05 · Genmab’s latest phase 2 data spur claim ADC is ‘clearly superior’ to AbbVie’s Elahere","url":"https://www.fiercebiotech.com/biotech/genmab-data-spur-claim-adc-clearly-superior-abbvies-elahere"},{"id":"sb:o/127d3e35738acf0add81adab","kind":"observation","label":"Clinical Trials Arena · 2026-10-05 · Genmab reports Phase I/II data for Rina-S in ovarian cancer","url":"https://www.clinicaltrialsarena.com/news/genmab-rina-s-data-ovarian-cancer/"},{"id":"sb:o/8a6dbdd3a8fa813df4154290","kind":"observation","label":"European Medical Journal · 2026-10-04 · Pembrolizumab-Olaparib Delays Ovarian Cancer Progression","url":"https://www.emjreviews.com/oncology/news/pembrolizumab-olaparib-delays-ovarian-cancer-progression/"},{"id":"sb:o/0477f33f1f92913ab49329a4","kind":"observation","label":"Financial Post · 2026-10-04 · Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026","url":"https://financialpost.com/pmn/business-wire-news-releases-pmn/agenus-reports-48-estimated-three-year-survival-with-botbal-in-recurrent-ovarian-cancer-at-igcs-2026"},{"id":"sb:o/02657c30e1da307330e91564","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-30 · Silent, but not innocent: the emerging role of clonal hematopoiesis in predicting therapy-related myeloid neoplasms","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1943135"},{"id":"sb:o/6785b0274f9c78c5e78a6394","kind":"observation","label":"Frontiers Precision Oncology · 2026-09-24 · Prospective multicenter study evaluating safety, tolerability and metabolism of niraparib as maintenance for ovarian cancer in women of African ancestry","url":"https://www.frontiersin.org/articles/10.3389/fonc.2026.1976278"},{"id":"sb:o/ea7d337464bc7554ad7e121e","kind":"observation","label":"Latest Science News -- ScienceDaily · 2026-09-23 · This new drug could break cancer’s resistance to treatment","url":"https://www.sciencedaily.com/releases/2026/09/260921081112.htm"}],"cursor":"c1.eyJpZCI6InNiOmUvNDYyYjg0Njg0YTU0NWRkZWM5ZDQ4YTA5IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTA2VDE0OjU5OjM4LjU1MDcyOSswMDowMCJ9","order":"newest first; we keep the 12 newest receipts for this entity. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":2,"byKind":{"co-mentioned":2},"items":[{"kind":"relation","label":"co-mentioned with immunotherapy (10 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/4215a04d08b0c35aa00aba46"},{"kind":"relation","label":"co-mentioned with breast cancer (8 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/1b9fe260cb87869e54b174f0"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/462b84684a545ddec9d48a09","mcp":"traverse {\"id\":\"sb:e/462b84684a545ddec9d48a09\"}","page":"/entity/parp/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/462b84684a545ddec9d48a09\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/462b84684a545ddec9d48a09\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"cantina","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/462b84684a545ddec9d48a09\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"cantina","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"cantina","call":"traverse {\"id\":\"sb:e/462b84684a545ddec9d48a09\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"cantina","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history (EQ-REPLAY), which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"cantina","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"cantina","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"workshop","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"workshop","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"docking-bay","reason":"one-time Reads are parked until the Commander decides their shape (#938)"}]}